Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide
GSH is the central reference antioxidant for studying redox signaling, free-radical chemistry, and cellular oxidative-stress responses
With athletes curious about taking them, it's such a nuanced conversation. Sometimes an athlete has been doing everything righttraining, sleeping, eatingand cant seem to unlock that next level
211 GMVs may help advance equitable obesity care: a retrospective study among majority Latino and low-income households in a federally designated underserved area found greater absolute weight reduction (12 vs 4 pounds) and meaningful weight reduction (55% vs 11% with 7%+ weight reduction) with GMVs vs individual visits
Patients should be encouraged to consume a varied, nutrient-dense diet rich in: Iron found in red meat, poultry, fish, lentils, and fortified cereals Zinc present in shellfish, meat, seeds, and nuts Vitamin D obtained through sunlight exposure, oily fish, and fortified foods B vitamins , particularly B12 found in animal products and fortified alternatives For patients struggling to meet nutritional requirements through diet alone, a standard multivitamin supplement within recommended daily allowance (RDA) limits may be considered after discussion with a healthcare professional
